{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:47:59Z","timestamp":1791924479723,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This study aimed to identify novel prognostic factors for Morbihan disease (MD) treatment outcomes and evaluate the efficacy of combination therapy in an Asian population, addressing the gaps in current understanding of this rare condition.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective analysis of MD patients diagnosed and treated at a tertiary hospital between 2017 and 2023. Patients received combinations of oral medications (tetracycline, isotretinoin, corticosteroids), topical treatments (tacrolimus, ivermectin), and intralesional steroid injections. Treatment response (TR) was defined as complete symptom remission, while partial remission or recurrence was considered a poor response (PR). Clinical, histological, and biochemical parameters were analyzed to identify prognostic factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study included 24 patients (18 men; mean age 61.3 years). Ten patients (41.7%) achieved TR, while 14 (58.3%) showed PR. Significant prognostic factors for TR included shorter symptom duration (\u2264\u20093 months, <jats:italic>p<\/jats:italic>\u2009=\u20090.016), lower LDL cholesterol levels (\u2264\u200989\u00a0mg\/dL, <jats:italic>p<\/jats:italic>\u2009=\u20090.046), combination treatment with oral and topical medications (<jats:italic>p<\/jats:italic>\u2009=\u20090.033 at 6 months), and partial response at 1 month (<jats:italic>p<\/jats:italic>\u2009=\u20090.017). GLMM analysis identified the number of visits (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), symptom duration (<jats:italic>p<\/jats:italic>\u2009=\u20090.020), and dyslipidemia (<jats:italic>p<\/jats:italic>\u2009=\u20090.006) as significant prognostic factors. Histologically, perivascular and perifollicular lymphocytic infiltration were the most common findings (83.3%). Notably, 50% of patients were ANA-positive, challenging previous diagnostic criteria.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study identifies novel prognostic factors for favorable outcomes in MD, including early intervention and lipid management. Combination therapy, particularly with tacrolimus ointment, shows promise in improving treatment responses. These findings suggest a potential link between lipid metabolism and MD pathophysiology, opening new avenues for targeted therapies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-024-03758-2","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T10:46:39Z","timestamp":1731494799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Novel prognostic factors and combination therapy outcomes in Morbihan disease: insights from an Asian population"],"prefix":"10.1186","volume":"24","author":[{"given":"Jungyul","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon-Bum","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk-woo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"3758_CR1","first-page":"120","volume":"133","author":"A Schimpf","year":"1956","unstructured":"Schimpf A. Dermatitis frontalis granulomatosa. Derm Wschr. 1956;133:120.","journal-title":"Derm Wschr"},{"issue":"80","key":"3758_CR2","first-page":"257","volume":"80","author":"R Degos","year":"1973","unstructured":"Degos R, Civatte J, Beuve-Mery M. Nouveau cas d\u2019oed\u00e8me \u00e9ryth\u00e9mateux facial chronique. Bull Soc Fr Dermatol Syph. 1973;80(80):257.","journal-title":"Bull Soc Fr Dermatol Syph"},{"issue":"12","key":"3758_CR3","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1016\/S0161-6420(00)00429-2","volume":"107","author":"FP Bernardini","year":"2000","unstructured":"Bernardini FP, Kersten RC, Khouri LM, Moin M, Kulwin DR, Mutasim DF. Chronic eyelid lymphedema and acne rosacea. Report of two cases. Ophthalmolgy. 2000;107(12):2220\u20133.","journal-title":"Ophthalmolgy"},{"issue":"3S Suppl 1","key":"3758_CR4","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1097\/IOP.0000000000000581","volume":"33","author":"BP Carruth","year":"2017","unstructured":"Carruth BP, Meyer DR, Wladis EJ, et al. Extreme eyelid lymphedema associated with rosacea (Morbihan disease): case series, literature review, and therapeutic considerations. Ophthalmic Plast Reconstr Surg. 2017;33(3S Suppl 1):S34\u20138.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"5","key":"3758_CR5","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/IOP.0000000000001589","volume":"36","author":"C Yvon","year":"2020","unstructured":"Yvon C, Mudhar HS, Fayers T, et al. Morbihan syndrome, a UK case series. Ophthalmic Plast Reconstr Surg. 2020;36(5):438\u201343.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"4","key":"3758_CR6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaad.2004.08.061","volume":"52","author":"J Wohlrab","year":"2005","unstructured":"Wohlrab J, Lueftl M, Marsch WC. Persistent erythema and edema of the midthird and upper aspect of the face (morbus morbihan): evidence of hidden immunologic contact urticaria and impaired lymphatic drainage. J Am Acad Dermatol. 2005;52(4):595\u2013602.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3758_CR7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.5021\/ad.2019.31.2.196","volume":"31","author":"JE Kim","year":"2019","unstructured":"Kim JE, Sim CY, Park AY, et al. Case Series of Morbihan disease (extreme eyelid oedema associated with rosacea): diagnostic and therapeutic approaches. Ann Dermatol. 2019;31(2):196\u2013200.","journal-title":"Ann Dermatol"},{"issue":"6","key":"3758_CR8","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1529-8019.2010.01373.x","volume":"23","author":"H Ranu","year":"2010","unstructured":"Ranu H, Lee J, Hee TH. Therapeutic hotline: successful treatment of Morbihan\u2019s disease with oral prednisolone and doxycycline. Dermatol Ther. 2010;23(6):682\u20135.","journal-title":"Dermatol Ther"},{"issue":"12","key":"3758_CR9","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1001\/archdermatol.2012.3109","volume":"148","author":"LA Smith","year":"2012","unstructured":"Smith LA, Cohen DE. Successful long-term use of oral isotretinoin for the management of Morbihan disease: a case series report and review of the literature. Arch Dermatol. 2012;148(12):1395\u20138.","journal-title":"Arch Dermatol"},{"issue":"2","key":"3758_CR10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4103\/2229-5178.110639","volume":"4","author":"S Veraldi","year":"2013","unstructured":"Veraldi S, Persico MC, Francia C. Morbihan syndrome. Indian Dermatol Online J. 2013;4(2):122\u20134.","journal-title":"Indian Dermatol Online J"},{"issue":"10","key":"3758_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/DAD.0000000000001378","volume":"41","author":"JL Ramirez-Bellver","year":"2019","unstructured":"Ramirez-Bellver JL, P\u00e9rez-Gonz\u00e1lez YC, Chen KR, et al. Clinicopathological and immunohistochemical study of 14 cases of Morbihan disease: an insight into its pathogenesis. Am J Dermatopathol. 2019;41(10):701\u201310.","journal-title":"Am J Dermatopathol"},{"issue":"2","key":"3758_CR12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/IOP.0000000000001229","volume":"35","author":"RS Boparai","year":"2019","unstructured":"Boparai RS, Levin AM, Lelli GJ. Morbihan disease treatment: two case reports and a systematic literature review. Ophthalmic Plast Reconstr Surg. 2019;35(2):126\u201332.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"4","key":"3758_CR13","doi-asserted-by":"publisher","first-page":"e12609","DOI":"10.1111\/dth.12609","volume":"31","author":"A Tsiogka","year":"2018","unstructured":"Tsiogka A, Koller J. Efficacy of long-term intralesional triamcinolone in Morbihan\u2019s disease and its possible association with mast cell infiltration. Dermatol Ther. 2018;31(4):e12609.","journal-title":"Dermatol Ther"},{"issue":"6","key":"3758_CR14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/DAD.0000000000001567","volume":"42","author":"IE Belousova","year":"2020","unstructured":"Belousova IE, Kastnerova L, Khairutdinov VR, Kazakov DV. Unilateral periocular intralymphatic histiocytosis, associated with rosacea (Morbihan disease). Am J Dermatopathol. 2020;42(6):452\u20134.","journal-title":"Am J Dermatopathol"},{"issue":"4","key":"3758_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3109\/01676831003695735","volume":"29","author":"R Chalasani","year":"2010","unstructured":"Chalasani R, McNab A. Chronic lymphedema of the eyelid: case series. Orbit. 2010;29(4):222\u20136.","journal-title":"Orbit"},{"issue":"12","key":"3758_CR16","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s001050050851","volume":"49","author":"T Jansen","year":"1998","unstructured":"Jansen T, Regele D, Schirren CG, Trautner B, Plewig G. [Persistent erythema and edema of the face associated with rosacea and lymph vessel dysplasia]. Hautarzt. 1998;49(12):932\u20135.","journal-title":"Hautarzt"},{"issue":"6","key":"3758_CR17","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1111\/j.1365-2133.1997.tb01577.x","volume":"137","author":"C Mazzatenta","year":"1997","unstructured":"Mazzatenta C, Giorgino G, Rubegni P, de Aloe G, Fimiani M. Solid persistent facial oedema (Morbihan\u2019s disease) following rosacea, successfully treated with isotretinoin and ketotifen. Br J Dermatol. 1997;137(6):1020\u20131.","journal-title":"Br J Dermatol"},{"issue":"1","key":"3758_CR18","first-page":"32","volume":"12","author":"V Olvera-Cort\u00e9s","year":"2019","unstructured":"Olvera-Cort\u00e9s V, Pulido-D\u00edaz N. Effective treatment of Morbihan\u2019s disease with long-term isotretinoin: a report of three cases. J Clin Aesthet Dermatol. 2019;12(1):32\u20134.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"6","key":"3758_CR19","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/1346-8138.13756","volume":"44","author":"A Okubo","year":"2017","unstructured":"Okubo A, Takahashi K, Akasaka T, Amano H. Four cases of Morbihan disease successfully treated with doxycycline. J Dermatol. 2017;44(6):713\u20136.","journal-title":"J Dermatol"},{"issue":"4","key":"3758_CR20","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.3390\/cimb45040177","volume":"45","author":"C Zhang","year":"2023","unstructured":"Zhang C, Kang Y, Zhang Z, et al. Long-term administration of LL-37 can induce irreversible Rosacea-like lesion. Curr Issues Mol Biol. 2023;45(4):2703\u201316.","journal-title":"Curr Issues Mol Biol"},{"issue":"10","key":"3758_CR21","first-page":"22","volume":"16","author":"MM van der Linden","year":"2023","unstructured":"van der Linden MM, Arents BW, van Zuuren EJ. Diagnosis and treatment of Morbihan\u2019s disease: a practical approach based on review of the literature. J Clin Aesthet Dermatol. 2023;16(10):22\u201330.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1","key":"3758_CR22","doi-asserted-by":"publisher","first-page":"e1361570","DOI":"10.1080\/19381980.2017.1361570","volume":"9","author":"MAD Rocha","year":"2017","unstructured":"Rocha MAD, Guadanhim LRS, Sanudo A, Bagatin E. Modulation of toll like receptor-2 on sebaceous gland by the treatment of adult female acne. Dermatoendocrinol. 2017;9(1):e1361570.","journal-title":"Dermatoendocrinol"},{"issue":"1","key":"3758_CR23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41392-022-00955-7","volume":"7","author":"P Kong","year":"2022","unstructured":"Kong P, Cui ZY, Huang XF, Zhang DD, Guo RJ, Han M. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther. 2022;7(1):131.","journal-title":"Signal Transduct Target Ther"},{"issue":"28","key":"3758_CR24","doi-asserted-by":"publisher","first-page":"23479","DOI":"10.1074\/jbc.M111.320960","volume":"287","author":"Y Kannan","year":"2012","unstructured":"Kannan Y, Sundaram K, Aluganti Narasimhulu C, Parthasarathy S, Wewers MD. Oxidatively modified low density lipoprotein (LDL) inhibits TLR2 and TLR4 cytokine responses in human monocytes but not in macrophages. J Biol Chem. 2012;287(28):23479\u201388.","journal-title":"J Biol Chem"},{"issue":"1","key":"3758_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12916-019-1433-3","volume":"17","author":"RA Jukema","year":"2019","unstructured":"Jukema RA, Ahmed TAN, Tardif JC. Does low-density lipoprotein cholesterol induce inflammation? If so, does it matter? Current insights and future perspectives for novel therapies. BMC Med. 2019;17(1):197.","journal-title":"BMC Med"},{"issue":"5","key":"3758_CR26","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/j.jaad.2020.04.113","volume":"83","author":"Q Chen","year":"2020","unstructured":"Chen Q, Shi X, Tang Y, et al. Association between rosacea and cardiometabolic disease: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;83(5):1331\u201340.","journal-title":"J Am Acad Dermatol"},{"key":"3758_CR27","doi-asserted-by":"publisher","first-page":"14345","DOI":"10.1038\/ncomms14345","volume":"8","author":"JC Gardenier","year":"2017","unstructured":"Gardenier JC, Kataru RP, Hespe GE, et al. Topical tacrolimus for the treatment of secondary lymphedema. Nat Commun. 2017;8:14345.","journal-title":"Nat Commun"},{"issue":"8","key":"3758_CR28","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1007\/s00403-023-02621-6","volume":"315","author":"O Mayur","year":"2023","unstructured":"Mayur O, Martinez R, McNichol MC, McGee JS. Clinical and histological features and treatment outcomes of patients with Morbihan disease: a systematic review. Arch Dermatol Res. 2023;315(8):2427\u20139.","journal-title":"Arch Dermatol Res"},{"issue":"7","key":"3758_CR29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/RHU.0b013e3181bb971b","volume":"15","author":"GG Marin","year":"2009","unstructured":"Marin GG, Cardiel MH, Cornejo H, Viveros ME. Prevalence of antinuclear antibodies in 3 groups of healthy individuals: blood donors, hospital personnel, and relatives of patients with autoimmune diseases. J Clin Rheumatol. 2009;15(7):325\u20139.","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"3758_CR30","first-page":"1","volume":"30","author":"A Wo\u017aniacka","year":"2013","unstructured":"Wo\u017aniacka A, Salamon M, McCauliffe D, Sysa-J\u0119drzejowska A. Antinuclear antibodies in rosacea patients. Postepy Dermatol Alergol. 2013;30(1):1\u20135.","journal-title":"Postepy Dermatol Alergol"},{"issue":"1","key":"3758_CR31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4048\/jbc.2023.26.e2","volume":"26","author":"FC Gulmark Hansen","year":"2023","unstructured":"Gulmark Hansen FC, J\u00f8rgensen MG, S\u00f8rensen JA. Treatment of breast cancer-related lymphedema with topical tacrolimus: a prospective, open-label, single-arm, phase II pilot trial. J Breast Cancer. 2023;26(1):46\u201359.","journal-title":"J Breast Cancer"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03758-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-024-03758-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03758-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T11:02:12Z","timestamp":1731495732000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-024-03758-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3758"],"URL":"https:\/\/doi.org\/10.1186\/s12886-024-03758-2","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"assertion":[{"value":"1 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants in this study were conducted in accordance with the ethical standards of the institutional and\/or national research committees, as well as with the 1964 Declaration of Helsinki and its subsequent amendments or comparable ethical standards. This study was approved by the Institutional Review Board of Pusan National University Hospital (IRB no. 2105-040-103). Informed consent was obtained from all participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"496"}}